ACM
QNCX icon

ADAR1 Capital Management’s Quince Therapeutics QNCX Stock Holding History

ADAR1 Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.07K Sell
250
-150
-38% -$30.1K ﹤0.01% 309
2025
Q4 		$268K Buy
+400
New +$201K 0.02% 214

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

ADAR1 Capital Management's QNCX Position: Q1 2026 in Review

ADAR1 Capital Management increased its Quince Therapeutics (QNCX) stake by 17% in Q1 2026, buying an estimated $7.23K and bringing the position to 251 shares worth $5.08K. The position accounts for ﹤0.01% of the portfolio, ranked #308.

ADAR1 Capital Management first reported a position in QNCX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.26M in Q3 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • ADAR1 Capital Management held 251 shares of Quince Therapeutics worth $5.08K as of Q1 2026.
  • ADAR1 Capital Management bought 36 Quince Therapeutics shares in Q1 2026, an estimated $7.23K.
  • Quince Therapeutics made up ﹤0.01% of ADAR1 Capital Management's portfolio in Q1 2026, its #308 holding.
  • ADAR1 Capital Management first reported a position in Quince Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • ADAR1 Capital Management's Quince Therapeutics position peaked at $1.26M in Q3 2025.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.